The stock of ProQR Therapeutics N.V (PRQR) has gone up by 23.06% for the week, with a 39.71% rise in the past month and a 66.08% rise in the past quarter. The volatility ratio for the week is 5.50%, and the volatility levels for the past 30 days are 5.76% for PRQR. The simple moving average for the past 20 days is 24.00% for PRQR’s stock, with a 3.94% simple moving average for the past 200 days.
Is It Worth Investing in ProQR Therapeutics N.V (NASDAQ: PRQR) Right Now?
Additionally, the 36-month beta value for PRQR is 0.36. There are mixed opinions on the stock, with 6 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for PRQR is 72.22M and currently, short sellers hold a 0.89% ratio of that float. The average trading volume of PRQR on June 27, 2025 was 499.19K shares.
PRQR) stock’s latest price update
ProQR Therapeutics N.V (NASDAQ: PRQR)’s stock price has plunge by 9.95relation to previous closing price of 2.16. Nevertheless, the company has seen a 23.06% surge in its stock price over the last five trading sessions. globenewswire.com reported 2025-06-26 that LEIDEN, Netherlands & CAMBRIDGE, Mass., June 26, 2025 (GLOBE NEWSWIRE) — ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced the submission of a Clinical Trial Application (CTA) to the European Medicines Agency (EMA) to initiate a Phase 1 clinical trial of its lead pipeline program AX-0810 targeting NTCP, a liver cell protein that transports bile acids into cells. AX-0810 is an investigational ADAR-mediated RNA editing oligonucleotide (EON) designed to selectively modulate NTCP function by reducing toxic bile acid accumulation in the liver, potentially mitigating inflammation, fibrosis, and progression toward liver failure, which are common in cholestatic diseases.
Analysts’ Opinion of PRQR
Many brokerage firms have already submitted their reports for PRQR stocks, with Cantor Fitzgerald repeating the rating for PRQR by listing it as a “Overweight.” The predicted price for PRQR in the upcoming period, according to Cantor Fitzgerald is $8 based on the research report published on April 29, 2025 of the current year 2025.
Evercore ISI, on the other hand, stated in their research note that they expect to see PRQR reach a price target of $5. The rating they have provided for PRQR stocks is “Outperform” according to the report published on April 29th, 2025.
Citigroup gave a rating of “Buy” to PRQR, setting the target price at $4 in the report published on March 10th of the current year.
PRQR Trading at 38.22% from the 50-Day Moving Average
After a stumble in the market that brought PRQR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -48.59% of loss for the given period.
Stock Fundamentals for PRQR
Current profitability levels for the company are sitting at:
- -1.76 for the present operating margin
- 0.96 for the gross margin
The net margin for ProQR Therapeutics N.V stands at -1.59. The total capital return value is set at -0.28. Equity return is now at value -52.64, with -21.73 for asset returns.
Based on ProQR Therapeutics N.V (PRQR), the company’s capital structure generated 0.18 points at debt to capital in total, while cash flow to debt ratio is standing at -2.2. The debt to equity ratio resting at 0.21. The interest coverage ratio of the stock is -12871.24.
Currently, EBITDA for the company is -24.12 million with net debt to EBITDA at 4.25. When we switch over and look at the enterprise to sales, we see a ratio of 5.25. The receivables turnover for the company is 6.89for trailing twelve months and the total asset turnover is 0.13. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.10.
Conclusion
In conclusion, ProQR Therapeutics N.V (PRQR) has seen better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
